Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue

In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow, as far as patient advocacy groups were concerned.

Not anymore.

On one hand, a new survey found, 60% of patient groups believed brand-name drugmakers maintained an “excellent” or “good” corporate reputation in 2022, which was up ever-so-slightly from 59% the year before. This was the best showing since the survey was launched in 2011 by PatientView, a research firm that canvassed 2,207 patient groups from 90 countries between November 2022 and February 2023.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In